» Articles » PMID: 33556957

The Importance of Understanding the Stages of COVID-19 in Treatment and Trials

Abstract

COVID-19, caused by SARS-CoV-2, continues to be a major health problem since its first description in Wuhan, China, in December 2019. Multiple drugs have been tried to date in the treatment of COVID-19. Critical to treatment of COVID-19 and advancing therapeutics is an appreciation of the multiple stages of this disease and the importance of timing for investigation and use of various agents. We considered articles related to COVID-19 indexed on PubMed published January 1, 2020-November 15, 2020, and considered papers on the medRxiv preprint server. We identified relevant stages of COVID-19 including three periods: pre-exposure, incubation, and detectable viral replication; and five phases: the viral symptom phase, the early inflammatory phase, the secondary infection phase, the multisystem inflammatory phase, and the tail phase. This common terminology should serve as a framework to guide when COVID-19 therapeutics being studied or currently in use is likely to provide benefit rather than harm.

Citing Articles

US Real-World Effectiveness Study of Nirmatrelvir/Ritonavir in Preventing Hospitalization of High-Risk COVID-19 Patients.

Cullen M, Zhou X, Kelly S, Liang C, Li L, Shen R Curr Ther Res Clin Exp. 2024; 101:100757.

PMID: 39649410 PMC: 11625212. DOI: 10.1016/j.curtheres.2024.100757.


Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach.

Griffin D Open Forum Infect Dis. 2024; 11(9):ofae462.

PMID: 39220656 PMC: 11363684. DOI: 10.1093/ofid/ofae462.


Inilico assessment of hesperidin on SARS-CoV-2 main protease and RNA polymerase: Molecular docking and dynamics simulation approach.

Molaakbari E, Aallae M, Golestanifar F, Garakani-Nejad Z, Khosravi A, Rezapour M Biochem Biophys Rep. 2024; 39:101804.

PMID: 39193225 PMC: 11347860. DOI: 10.1016/j.bbrep.2024.101804.


Early inflammatory profiles predict maximal disease severity in COVID-19: An unsupervised cluster analysis.

Kenny G, Saini G, Gaillard C, Negi R, Alalwan D, Leon A Heliyon. 2024; 10(15):e34694.

PMID: 39144942 PMC: 11320140. DOI: 10.1016/j.heliyon.2024.e34694.


A prediction model for secondary invasive fungal infection among severe SARS-CoV-2 positive patients in ICU.

Su L, Yu T, Zhang C, Huo P, Zhao Z Front Cell Infect Microbiol. 2024; 14:1382720.

PMID: 39040601 PMC: 11260608. DOI: 10.3389/fcimb.2024.1382720.